Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528

NCT00116168 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

BIOLOGICAL: MEDI-528 0.3 mg/kg
BIOLOGICAL: MEDI-528 1 mg/kg
BIOLOGICAL: MEDI-528 3 mg/kg
BIOLOGICAL: MEDI-528 9 mg/kg

Sponsor

MedImmune LLC